[company_age]13.0[/company_age][employees]11-50 employees[/employees][funding]Series B[/funding][description]Acesion Pharma is a Danish biotech company established in 2011 and headquartered in Copenhagen. The company focuses on developing innovative and safer medications for treating atrial fibrillation (AF), the most prevalent cardiac arrhythmia. Acesion Pharma's scientific foundation is built on the novel concept of inhibiting SK channels, ion channels in the heart that regulate cardiac rhythm. This unique approach distinguishes Acesion Pharma from its competitors, who primarily focus on traditional treatment methods for AF. Acesion Pharma's commitment to developing first-in-class drugs for AF positions it as a leader in the field of cardiac arrhythmia treatment.[/description][ps]First-in-class drugs for the treatment of atrial fibrillation[/ps]